KLP Kapitalforvaltning AS Raises Stake in Humana Inc. $HUM

KLP Kapitalforvaltning AS raised its position in Humana Inc. (NYSE:HUM) by 6.5% in the second quarter, Holdings Channel reports. The fund owned 44,370 shares of the insurance provider’s stock after buying an additional 2,700 shares during the period. KLP Kapitalforvaltning AS’s holdings in Humana were worth $10,881,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Humana by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after buying an additional 1,143,662 shares during the last quarter. Dodge & Cox lifted its position in shares of Humana by 5.5% during the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock worth $2,845,830,000 after buying an additional 557,175 shares during the last quarter. Pzena Investment Management LLC lifted its position in shares of Humana by 6.1% during the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider’s stock worth $1,013,133,000 after buying an additional 219,541 shares during the last quarter. Davis Selected Advisers lifted its position in shares of Humana by 3.3% during the 1st quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider’s stock worth $616,873,000 after buying an additional 74,434 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its position in Humana by 1.6% in the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider’s stock valued at $327,293,000 after purchasing an additional 19,613 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM opened at $290.11 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The stock has a market capitalization of $34.89 billion, a P/E ratio of 22.27, a P/E/G ratio of 1.75 and a beta of 0.42. The company’s fifty day moving average is $278.79 and its two-hundred day moving average is $258.16. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $315.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, September 26th. Humana’s dividend payout ratio (DPR) is currently 27.17%.

Wall Street Analysts Forecast Growth

HUM has been the subject of several research reports. Robert W. Baird reduced their price target on shares of Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Wall Street Zen downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Wells Fargo & Company upped their price target on shares of Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a research report on Tuesday. Bank of America upped their price target on shares of Humana from $285.00 to $312.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Finally, Sanford C. Bernstein boosted their price objective on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Seven investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $298.71.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.